Supplement to the prospectus relating to the invitation to subscribe for shares in Oncology Venture Sweden AB

About the supplementary prospectus

This prospectus supplement is a supplement to the prospectus relating to the offer to subscribe for shares in Oncology Venture Sweden AB, which has been prepared by the Board of Oncology Venture Sweden AB ("Oncology Venture"), corporate registration number 559016-3290. The company conducts a rights issue with subscription period 16 to 30 March 2017. The public is also given the opportunity to subscribe for shares in the rights issue. The Prospectus was approved and registered by the Swedish Financial Supervisory on March 14, 2017. Financial Supervisory registration number is 17-2251. The prospectus was published on March 14, 2017 and is available on the Company's and AktieTorget´s websites (www.oncologyventure.com and www.aktietorget.se).

The supplementary prospectus is a part of and should be read as part of the prospectus. The supplementary prospectus has been prepared in accordance with Chapter 2. 34 § The Act (1991: 980) regarding trading with financial instruments ("FITA") and was the 29 March, 2017 approved and registered by the Swedish Financial Supervisory Authority. Financial Supervisory registration number of the prospectus supplement is 17-4806. Date of publication of the prospectus supplement is 29 March 2017.

This supplementary prospectus has been prepared due to:

- Oncology Venture, March 21, 2017, after the Financial Supervisory Authority approved Oncology Ventures prospectus, issued a press release that the Danish Medicines Agency approved Oncology Ventures focused clinical study with APO010 in multiple myeloma.

- Oncology Venture, March 24, 2017, issued a press release that Oncology Venture evaluate an oncology drug from Eisai Inc. for licensing to 2X Oncology Inc.

- Oncology Venture, March 28, 2017, published a press release relating to Oncology Venture and 2-BBB Medicines BV concluded a global exclusive license of 2-BBBs leading phase 2 2B3-101 product (now referred to as 2X-111).

- Oncology Venture, March 29, 2017, issued a press release that investors have agreed to subscribe for an additional approximately 5.1 MSEK in Oncology Ventures ongoing rights issue.

The additional information is added in Oncology Ventures prospectus on the following pages:

Page 4-5, B.3 " Virksomhed"

Paragraph two under "Operations" is replaced by the following paragraph: Oncology Venture arbejder med en model, som ændrer oddsene, sammenlignet med sædvanlig lægemiddeludvikling. I stedet for at behandle alle patienter med lægemidlet, screenes patienterne først, og kun de, der forventes at respondere på behandlingen, bliver behandlet. Gennem en mere veldefineret patientgruppe mindskes dermed både risiko og omkostninger, samtidig med at udviklingen af lægemidler bliver mere effektiv. Selskabet har tre indlicenserede lægemiddelkandidater: APO010, Irofulven og LiPlaCis©. I et fase 1/2 studie med LiPlaCis© for vurdering af sikkerhed og tolerabilitet er fase 1 (dosisskaleringsdelen) med patienter med avancerede tumorer gennemført. Fase 1-delen er afsluttet, og fase 2-delen af studiet forventes af blive afsluttet i løbet af det tredje kvartal 2017. Herudover er Oncology Ventures partner Cadila Pharmaceuticals Ltd. i færd med at indlede fire fase 2-studier og et fase 3-studie med LiPlaCis©. Oncology Venture har i APO010-programmet til hensigt at screene cirka 150 patienter for blandt disse at identificere de 15 patienter med størst sandsynlighed for at få gavn af at deltage i et fokuseret fase 2-studie. APO010 er i tidlig klinisk fase 1/2- udvikling. Den danske Lægemiddelstyrelsen godkendte i marts 2017 Oncology Ventures fokuserede kliniske studie med APO010 i mylometose. Godkendelsen betyder, at lageret af APO010 kan bruges i undersøgelsen. Undersøgelsen vil begynde i maj 2017.

Page 5, B.3 " Virksomhed"

The following will be added in the third paragraph: Oncology Venture har indgået en aftale med Eisai Inc. under hvilke Oncology Venture vil udvikle companion diagnostics (ved hjælp af DRP™ teknologi), for et ikke offentliggjort onkologi terapeutisk lægemiddelkandidat fra Eisai Inc. Det er hensigten at evaluere Oncology Ventures interesse i at få en licens til lægemidlet til klinisk udvikling i Oncology Ventures spin-out virksomhed, 2X Oncology Inc. Lægemidlet er i fase 2 og small molecule inhibitors har lovende anvendelse i et antal humane kræftformer. Hvis DRP™-evalueringen er en succes, vil Oncology Venture indgå en eksklusiv licensaftale til yderligere udvikling i 2X Oncology Inc. De lægemiddelspecifikke

DRP-biomarkører kan således anvendes som companion diagnostics til at vælge og inkludere de kræftpatienter, der er mest tilbøjelige til at få gavn af behandling i et fase 2-studie.

Page 5, B.3 " Virksomhed"
The following will be added in the third paragraph: Oncology Venture og 2-BBB Medicines BV ("2-BBB") i marts 2017 indgået en eksklusiv global licens til 2-BBBs ledende fase 2 produkt 2B3-101 – nu kaldet 2X-111. Medikamentet er en liposomal formulering af doxorubicin, der bruger den såkaldte G-teknologi, der tillader lægemidlet at passere blod-hjerne-barrieren for at forbedre behandlingen af hjernemetastaser og primære hjernetumorer. 2X-111 har vist klinisk aktivitet i et fase 2-studie af patienter med metastatiske brystcancerpatienter og patienter med glioblastom (primær hjernekræft), der er både svært behandelige kræftformer med et stort medicinsk behov. 2X-111 vil blive kombineret med sin Drug Response Predictor (DRP™) som companion diagnostic i DRP™-fokuserede fase 2-studier i patienter med høj sandsynlighed for at reagere på behandling. Oncology Venture vil med 2x Onkologi, finansiere og gennemføre fælles vedtaget klinisk udvikling.

Page 9, B.11 " Utilstrækkelig driftskapital"
The following paragraph will be added: I løbet af tegningsperioden har Oncology Venture modtaget yderligere aftale om tegningstilsagn fra investorer, der er aftalt at tegne yderligere 5,1 MSEK i emissionen.

*Page 21, under the heading "*SINCE THE ISSUANCE OF NEW SHARES IN OCTOBER 2016, ONCOLOGY VENTURE HAS... *"*
The following paragraph will be added: entered into an exclusive global license agreement on 2-BBB's Phase 2 lead product 2B3-101.

Page 23, under the heading " THE CURRENT SITUATION AND THE PATH FORWARD*" with subheading "APO010"*
The section under "APO010" is replaced by the following paragraph: APO010 is currently in early clinical Phase 1/2 development. Oncology Venture has the intention, within the APO010 program, to screen approximately 150 patients for the purpose of identifying the 15 patients among them with the highest probability to benefit from participating in a focused Phase 2 clinical trial. The Danish Medicines Agency approved in March 2017 Oncology Ventures focused clinical study with APO010 in multiple myeloma. The approval means that the stocks of APO010 can be used in the study. The study will begin in May 2017. In June 2016, Oncology Venture received a grant for APO010 from EUROSTARS and the Company's CRO SMERUD of approximately SEK 13.5 million.

Page 24, under the heading "2X Oncology"
The following will be added in the first paragraph: Oncology Venture has entered an agreement with Eisai Inc. under which Oncology Venture will develop a companion diagnostic (utilizing its proprietary Drug Response Predictor (DRP™) technology) for an undisclosed Eisai oncology therapeutic agent in order to evaluate its interest in in-licensing the drug for further clinical development in the Oncology Venture spin-out, 2X Oncology Inc. The drug is Phase 2 stage, the targeted small molecule inhibitor having promising application in a number of human cancers. If the DRP™ evaluation is successful, Oncology Venture may exclusively in-license the drug for further development within and by 2X Oncology Inc. The drug-specific DRP™ biomarker would consequently be used as a predictive companion diagnostic to select and enroll likely responder patients with a women's cancer indication in a clinical Phase 2 trial.

Page 24, under the heading "2X Oncology"
The following will be added in the first paragraph: Oncology Venture and 2-BBB Medicines BV entered in March 2017 into an exclusive global license agreement on 2-BBB's Phase 2 lead product 2B3-101 – now called 2X-111. The drug is a liposomal formulation of doxorubicin utilizing the so-called G-Technology, which enables the drug to pass the Blood-Brain Barrier to enhance treatment of brain metastases and primary brain tumors. 2X-111 has demonstrated clinical activity in a phase 2 study in metastatic Breast Cancer patients and in patients with Glioblastoma (primary brain cancer), both hard to treat cancers with a huge unmet medical need. 2X-111 will be combined with its Drug Response Predictor (DRP™) as a companion diagnostic in DRP™ focused Phase 2 trials for selected, high-likelihood responder patients. Oncology Venture will, through 2X Oncology, fund and execute the mutually agreed upon clinical development plan.

Page 25, under the heading "Product pipeline and key dates"
The following is deleted in section 4: Term sheet signed. The following will be added in section 4: Agreement signed.

Page 25, under the heading" Product pipeline and key dates"
The following is deleted in section 5: Term sheet signed. The following will be added in section 5: Agreement signed.

Page 25, under the heading "Product pipeline and key dates"
The following is deleted: ** Regarding APO010, the Company is working to be able to use existing stocks of the medicine in the first indication of multiple myeloma, which would provide a real times saving as well as financial savings concerning production costs. The following will be added: **The Danish Medicines Agency approved in March 2017 Oncology Ventures focused clinical study with APO010 in multiple myeloma. The approval means that the stocks of APO010 can be used in the study.

Page 26, under the heading "The use of the proceeds of the issuance of new shares"
The following will be added in the first paragraph: During the subscription period Oncology Venture has received additional subscription commitment agreements from investors who agreed to subscribe for an additional 5.1 MSEK in the rights issue.

Page 26, under the heading "Future capital requirements"
The first paragraph under the section "Future capital" is replaced with the following paragraph: According to the assessment of the Board of Directors, a fully subscribed rights issue is expected to finance the Company's activities for at least 12 months following the date of receiving the additional capitalization. Oncology Venture's future capital requirements depends, above all, on what choices the Company elects from among each indication. According to the assessment of the Board of Directors, Oncology Venture's process with a drug candidate costs about USD 2 million, including licensing, clinical trials and out-licensing, depending upon the pharmaceutical manufacturing. Oncology Venture has the intention to in-license at least five drug candidates and carry out five small focused clinical Phase 2 studies of these drug candidates along with their DRPs within a period of three years from the time the company was listed on the exchange. Against the above background, the need for capital for these purposes amounts to approximately USD 10 million. Oncology Venture has raised capital previously via a public offering upon listing and preferential rights issues. The Danish Medicines Agency approved in March 2017 Oncology Ventures focused clinical study with APO010 in multiple myeloma. The approval means that the stocks of APO010 can be used in the study. The Board of Directors believes that the existing capital is sufficient to work with the development of APO010 and Irofulven up to the implementation of focused Phase 2 clinical trials and thereafter the planned out-licensing. Via the capital Oncology Venture was provided by means of the rights issue in May 2016, this made it possible for the Company to maintain a high pace of development with respect to LiPlaCis®. Immunotherapy (sometimes referred to as biologic therapy or biotherapy) is a growing area with very strong developments and an early out-licensing of APO010 is, in the judgment of the Board, as likely as for LiPlaCis® as well as Irofulven. The Board of Directors of Oncology Venture is therefore of the opinion that the Company have in-licensed three of five drug candidates, and with the potential drug candidates in the SPVs, Oncology Venture has co-ownership in up to seven drug candidates. The capital obtained from the rights issue implemented in May 2016 also related to financing the establishment of an international subsidiary in the United States (included in this, is organizational, legal advisory services, auditing and marketing) – known as a SPV – in order to expand the Company's product pipeline with additional drug projects beyond the above five drug candidates, in a shared ownership with future investors. The capital that was raised by means of the rights issue in October 2016 is primarily intended to finance the inlicensing and partially the development of an oral tyrosine kinase inhibitor for OV-SPV2, product manufacturing for the clinical trials that are being conducted in accordance with the Company's development agreement with Cadila, plus to secure the rights for 2X Oncology to particularly promising products for anticancer drugs in women.

Page 29, under the heading "THE OFFER IN SUMMARY"
The following will be added under the heading "Subscription commitments": During the subscription period Oncology Venture has received additional subscription commitment agreement from investors who agreed to subscribe for an additional 5.1 MSEK in the rights issue.

Page 30, under the heading "Subscription commitments"
The following will be added in the first and second paragraphs: During the subscription period Oncology Venture has received additional subscription commitment agreement from investors who agreed to subscribe for an additional 5.1 MSEK in the rights issue.

Page 35, under the heading "More detailed information about Oncology Venture's drug candidates"
The third paragraph under the section "APO010 – a powerful immune oncology product" is replaced with the following paragraph: Oncology Venture has the intention, within the APO010 program, to screen approximately 150 patients for the purpose of identifying the 15 patients among them with the highest probability to benefit from participating in a focused Phase 2 clinical trial. APO010 DRP™ is based on cell line analysis and the analysis of over 3,000 cancer patients. A Phase 1 dose-escalation study of 26 patients has previously been conducted. In this study, patients were not selected based on an individual probability of responding to APO010. In March 2016, the first patient in the screening study that

precedes a Phase 1/2 clinical trial was enrolled. All four planned centers have been included and initiated screening patients with multiple myeloma in Oncology Venture's APO010 study. The screening aims to identify 15 patients with multiple myeloma who will be included in a focused Phase 2 multicenter study. The Danish Medicines Agency approved in March 2017 Oncology Ventures focused clinical study with APO010 in multiple myeloma. The approval means that the stocks of APO010 can be used in the study. The study will begin in May 2017. The intention is to outlicense the project after the clinical trial has concluded – in the event the study shows good results.

Page 36, under the heading "More detailed information about Oncology Venture's spin-out companies"
The following will be added in the first paragraph: Oncology Venture has entered an agreement with Eisai Inc. under which Oncology Venture will develop a companion diagnostic (utilizing its proprietary Drug Response Predictor (DRP™) technology) for an undisclosed Eisai oncology therapeutic agent in order to evaluate its interest in in-licensing the drug for further clinical development in the Oncology Venture spin-out, 2X Oncology Inc. The drug is Phase 2 stage, the targeted small molecule inhibitor having promising application in a number of human cancers. If the DRP™ evaluation is successful, Oncology Venture may exclusively in-license the drug for further development within and by 2X Oncology Inc. The drug-specific DRP™ biomarker would consequently be used as a predictive companion diagnostic to select and enroll likely responder patients with a women's cancer indication in a clinical Phase 2 trial.

Page 36, under the heading "More detailed information about Oncology Venture's spin-out companies"
The following will be added in the first paragraph: Oncology Venture and 2-BBB Medicines BV entered in March 2017 into an exclusive global license agreement on 2-BBB's Phase 2 lead product 2B3-101 – now called 2X-111. The drug is a liposomal formulation of doxorubicin utilizing the so-called G-Technology, which enables the drug to pass the Blood-Brain Barrier to enhance treatment of brain metastases and primary brain tumors. 2X-111 has demonstrated clinical activity in a phase 2 study in metastatic Breast Cancer patients and in patients with Glioblastoma (primary brain cancer), both hard to treat cancers with a huge unmet medical need. 2X-111 will be combined with its Drug Response Predictor (DRP™) as a companion diagnostic in DRP™ focused Phase 2 trials for selected, high-likelihood responder patients. Oncology Venture will, through 2X Oncology, fund and execute the mutually agreed upon clinical development plan.

Page 39, under the heading "Significant agreements"
The following paragraph will be added: Licensing agreements with 2-BBB Medicines BV for the drug candidate 2X-111. *For further information, please refer to the heading "More detailed information about Oncology Venture's spin-out companies".*

Page 76, under the heading "Working capital"
The following paragraph will be added: During the subscription period Oncology Venture has received additional subscription commitment agreement from investors who agreed to subscribe for an additional 5.1 MSEK in the rights issue.

Right to withdraw

Investors who before the publication of the supplement prospectus, has subscribed for shares in the ongoing rights issue as described in the prospectus, in accordance with Chapter 2. 34 § Trading Act, have the right to withdraw their subscription of shares within two working days of publication of this prospectus, that is, by 31 March 2017. Timing or terms and conditions are not affected of this prospectus supplement.

Delivery of the prospectus supplement

The Board of Oncology Venture Sweden AB hereby delivers prospectus supplement. Supplementary prospectus is available on the company's and AktieTorget´s websites (www.oncologyventure.com and www.aktietorget.se).

Hørsholm, 29 March 2017
The Board of Oncology Venture Sweden AB

Duncan Moore – Chairman of the Board
Sanjeevi Carani – Board Member
Steen Knudsen – Board Member
Ulla Hald Buhl – Board Member
Peter Birk – Board Member